MedTrace Logo

Safety and Efficacy of IQP-MM-101 in Reducing Symptoms of Diarrhoea

NCT01969214 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2020-03-04

Study results available
· View outcomes & findings →

Summary

Diosmectite in IQP-MM-101 has been used for diarrhoea control. Backed by data from several studies demonstrating their efficacy, the investigators are conducting this study to look into the efficacy and safety of IQP-MM-101 in diarrhoea control.

Conditions

  • Diarrhoea

Interventions

DEVICE

IQP-MM-101

Dissolve the effervescent tablets in half a glass of water, to be taken orally 1 tablet, 3 times a day

Sponsors & Collaborators

  • InQpharm Group

    lead INDUSTRY

Principal Investigators

  • Ralf Uebelhack · analyze & realize GmbH

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2014-06-30
Completion
2014-07-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01969214 on ClinicalTrials.gov